GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum [Yahoo! Finance]
Monte Rosa Therapeutics announces pricing of $300M stock offering [Seeking Alpha]
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $22.00 to $30.00. They now have an "overweight" rating on the stock.
Form 8-K Monte Rosa Therapeutics, For: Jan 08
Form 424B5 Monte Rosa Therapeutics,
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
Form 4 Monte Rosa Therapeutics, For: Jan 07 Filed by: Warmuth Markus
Form 144/A Monte Rosa Therapeutics, Filed by: Warmuth Markus
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.